Statins and Coenzyme Q10 deficiency

Statins drugs reduce coenzyme q10 inside the body

Medical literature clearly shows that statins, drugs such as Lipitor, Crestor, Zocor stop the endogenous production of one of the most important nutrients for the cells in our body: coenzyme Q10.

Many people are unaware that the depletion of Q10 causes the oxidation of LDL cholesterol. This triggers a series of cascading events on the arterial wall, where the inflammation increases the risk of heart attack and stroke.

This is just one of the reasons why statins do not guarantee protection from heart attack.

The prescription of statins without Q10 should be considered illegal.

The list of health problems related to depletion of Q10 should invite us to reflect on the safety of statins.

The Coenzyme Q10 deficiency can cause:

fatal cardiomyopathy, heart attack, congestive heart failure (which usually brings to death within 5 years), fatigue, cancer, myopathy, depression resistant to anti-depressants, high blood pressure, gum disease and tooth loss, hair loss, liver disease, sudden complete loss of memory or amnesia, cataracts, angina, folic acid deficiency, damage to cell membranes and more.

In fact, low levels of Q10 in addition to increasing disease, can cause death within six months.

The literature referred to at the bottom of the article, should encourage every doctor to prescribe Q10 as often as prescribed statins.

You may feel as bold as you just read, but the severity of the problem remains and needs to be understood.

So why not producing statins with Q10?

Already in 1990, the pharmaceutical giant Merck, has decided to add Q10 to a statin drug. They were also about to obtain a patent. The patent number is 4.933.165.

Why has the drug never been commercialized?

How not to suspect that the drug companies already knew from the beginning the seriousness and the effects produced by statins without Q10?

If you take statins, insist to your doctor to control the Q10 levels.

Insights on micronutrients necessary to the cardiovascular system can be received by subscribing the newsletter below, after the references.


Thomas S. R., Neuzil J., Stocker R, Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism of coenzyme Q in atherogenesis? Mol Asp Med, 18 (suppl.): s 85-103, 1997

Bargossi AM, Battino M, Gaddi A, et at. Exogenous CoQ10 preserves plasma ubiquinol levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, Internal J Clin Lab Res, 24: 171-6, 1994

Fuke C, Krikorian, SA, Couris RR, Coenzyme CoQ10: A review of essential functions and clinical trials, Pharmacist, 28-41, Oct 2000

Langsjoen PH, Langsjoen AM, Coenzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischaemia, Asia Pacific Heart J ,7; 3: 160-168, 1998

Langsjoen PH, et al, Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation, BioFactors, 25 (1-4): 147-52, 2005

Langsjoen PH, et al, The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications, BioFactors, 18 (1-4): 101-11, 2003

Mabuchi H, et al, Reduction of serum ubiquinol-10 and a ubiquinone-10 levels by atorvastatin in hypercholesterolemia, patients, J Atheroscler Thromb, 12; 2:111-19, 2005

Lamperti C, Muscle, coenzyme Q10 level in statin-related myopathy, Arch Neurol, 62; 11: 1109-12, Nov 2005

Mortensen AS, et al, Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure, Int J Tissue React, 12; 3: 155-62, 1990

Folkers K, Langsjoen P, Tamagawa H, Lovastatin decreases coenzyme levels in humans, Proc Nall Acad Sci USA, 1990; 87:8931-34

Bliznakov EG, Wilkins DJ, Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid-lowering HMG COA reductase inhibitors (statins): a critical overview, Advances in Therapy, 15; 4:219-28, Jul/Aug 1998

Ghirlanda G, Oradei A, Manto A, et al, Evidence of plasma CoQ 10-lowering effect of HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study, J Clin Pharmacol, 33: 226-29, 1993

Willis RA. Folkers K, Tucker JL, Tamagawa H., et al., Lovastatin decreases coenzyme Q levels in rats, Proc Nat Acad Sci USA, 87: 8928-30. 1990

Folkers K, Langsjoen P, et al, Lovastatin decreases coenzyme Q10 levels in humans, Proc Nat Acad Sci USA, 87:8931-4, 1990

Bliznakov EG, Lipid-lowering to drugs (statins), cholesterol, and coenzyme Q10. The Baycol case-¬-a modern Pandora’s box, Biomed Pharmacother, 56:56-9, 2002

Jameson S, Statistical data support prediction of death within six months on low levels of coenzyme Ql0 and other entities, Clin Invest, 71 (suppl):137-39, 1993

You can download for free the complete E-Book “Why Animals Don’t Get Heart Attacks… But People Do!”.

Sign up for Newsletter to receive documented results of a group of researchers focused on natural compounds.

Book of dr Rath

Post a comment